Home  |  Contact

Cellosaurus HEL/TGR (CVCL_4Z61)

[Text version]
Cell line name HEL/TGR
Accession CVCL_4Z61
Resource Identification Initiative To cite this cell line use: HEL/TGR (RRID:CVCL_4Z61)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:90304; TG101209 (N-(tert-butyl)-3-((5-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)benzenesulfonamide).
Donor information: Originally the patient was suffering from Hodgkin lymphoma.
Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
Sequence variations
  • Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 11998; TP53; Simple; p.Met133Lys (c.398T>A); ClinVar=VCV002430159; Zygosity=Homozygous (from parent cell line).
Disease Erythroleukemia (NCIt: C7152)
Acute erythroid leukemia (ORDO: Orphanet_318)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_2481 (HEL 92.1.7)
Sex of cell Male
Age at sampling 30Y
Category Cancer cell line
Publications

PubMed=21976548; DOI=10.1158/1078-0432.CCR-11-1541
Fiskus W., Verstovsek S., Manshouri T., Rao R., Balusu R., Venkannagari S., Nalabothula N., Ha K., Smith J.E., Hembruff S.L., Abhyankar S., McGuirk J.P., Bhalla K.N.
Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
Clin. Cancer Res. 17:7347-7358(2011)

Cross-references
Cell line databases/resources cancercelllines; CVCL_4Z61
Encyclopedic resources Wikidata; Q54882508
Entry history
Entry creation14-Dec-2015
Last entry update05-Oct-2023
Version number11